← Leaderboards
Srikanth Singamsetty
Phoenix Nest, Inc.
$8,567,056
Attributed
$8,679,492
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,679,492 · 4
By mechanism
R44$4,934,685 · 2
UB1$3,519,934 · 1
R41$224,873 · 1
Top collaborators
- Geoffrey A Chang1 shared
Others in their field
Other Emerging Leaders on “Neurologic”
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$21,828,548
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
- Thomas Blanchard · University Of Maryland Baltimore$14,770,566
- Kevin Navin Sheth · Brigham And Women'S Hospital$12,820,802
- Sharon Dziuba Yeatts · University Of Michigan At Ann Arbor$12,707,141
- Hemali Phatnani · New York University School Of Medicine$11,819,164
Research focus
NeurologicNerve DegenerationMucopolysaccharidosis IiiChildhoodPathologyAffectDementiaEnzyme Replacement TherapyRare DiseasesCessation Of LifeRecommendationImpaired CognitionClinical TrialsSmall Business Innovation Research GrantMotor SkillsMucopolysaccharidosesProblem BehaviorCommercializationDesignConsultationsGrantClinicLegal PatentDiagnosis
Grant awards (10)
Identification of Potential Biomarkers and Clinical Tools for use in Mucopolysaccharidosis IIIC Patients.$1,062,505
R44 · FY2025 · NS · contact PI
Identification of Potential Biomarkers and Clinical Tools for use in Mucopolysaccharidosis IIIC Patients.$881,675
R44 · FY2024 · NS · contact PI
Evaluation of Clinical Outcome Assessment (COA) and Potential Biomarkers to Facilitate Interventional Trial for Mucopolysaccharidosis IIID Patients$798,341
UB1 · FY2024 · NS · contact PI
Evaluation of Clinical Outcome Assessment (COA) and Potential Biomarkers to Facilitate Interventional Trial for Mucopolysaccharidosis IIID Patients$100,000
UB1 · FY2024 · NS · contact PI
Development of Gene Replacement Therapy for Sanfilippo Syndrome Type C$1,494,895
R44 · FY2023 · NS · contact PI
Evaluation of Clinical Outcome Assessment (COA) and Potential Biomarkers to Facilitate Interventional Trial for Mucopolysaccharidosis IIID Patients$1,125,625
UB1 · FY2023 · NS · contact PI
Development of gene replacement therapy for Sanfilippo Syndrome Type C$1,495,610
R44 · FY2022 · NS · contact PI
Evaluation of clinical outcome assessment (COA) and potential biomarkers to Facilitate Interventionaltrial for Mucopolysaccharidosis IIID Patients$1,125,627
UB1 · FY2022 · NS · contact PI
Evaluation of clinical outcome assessment (COA) and potential biomarkers to Facilitate Interventionaltrial for Mucopolysaccharidosis IIID Patients$370,341
UB1 · FY2021 · NS · contact PI
Structure-based optimization of a novel pharmacological chaperone therapy for MPSIIIC$224,873
R41 · FY2017 · HD · contact PI